The compound you described, **2-(4-bromophenoxy)-N-[(2-hydroxy-5-methylanilino)-sulfanylidenemethyl]acetamide**, is a complex organic molecule that is likely a **synthetic compound** designed for specific research purposes.
Unfortunately, without additional context or information about its intended use, it's impossible to definitively say why this specific compound is important for research.
**Here's why it's difficult to determine its significance:**
* **No common name or abbreviation:** The compound has a very long and complex chemical name. Researchers usually assign shorter, more convenient names or abbreviations to compounds they work with.
* **Lack of established applications:** There are no readily available databases or publications that readily provide information on this specific compound and its potential applications.
* **Potential for diverse uses:** The compound could potentially be important for a range of research areas, such as:
* **Drug discovery:** It could be a novel lead compound for developing new drugs with therapeutic effects.
* **Materials science:** It might have unique properties that make it suitable for use in advanced materials.
* **Chemical biology:** It could be used as a probe to study specific biological processes.
**To determine the compound's importance, you would need additional information, such as:**
* **Research context:** What specific research project is this compound being used in?
* **Synthesis and characterization data:** How was the compound synthesized? What are its physical and chemical properties?
* **Biological or chemical activity:** Does the compound exhibit any interesting biological or chemical activity?
By providing more context, you can increase the chances of finding relevant information about this compound's importance for research.
ID Source | ID |
---|---|
PubMed CID | 1346745 |
CHEMBL ID | 1418754 |
CHEBI ID | 119946 |
SCHEMBL ID | 14096645 |
Synonym |
---|
MLS000689907 , |
smr000298589 |
2-(4-bromophenoxy)-n-{[(2-hydroxy-5-methylphenyl)amino]carbonothioyl}acetamide |
OPREA1_613354 |
2-(4-bromophenoxy)-n-[(2-hydroxy-5-methylphenyl)carbamothioyl]acetamide |
STK020591 |
CHEBI:119946 |
AKOS003224681 |
HMS2655K17 |
AB00112523-01 |
SCHEMBL14096645 |
CHEMBL1418754 |
2-(4-bromophenoxy)-n-[(2-hydroxy-5-methyl-phenyl)thiocarbamoyl]acetamide |
cid_1346745 |
2-(4-bromanylphenoxy)-n-[(5-methyl-2-oxidanyl-phenyl)carbamothioyl]ethanamide |
2-(4-bromophenoxy)-n-[(2-hydroxy-5-methylanilino)-sulfanylidenemethyl]acetamide |
bdbm90398 |
Q27207724 |
Class | Description |
---|---|
thioureas | Compounds of general formula RR'NC(=S)NR''R'''. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
TDP1 protein | Homo sapiens (human) | Potency | 24.8446 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
Microtubule-associated protein tau | Homo sapiens (human) | Potency | 5.6234 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
Smad3 | Homo sapiens (human) | Potency | 11.2202 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 2.8184 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 70.7946 | 0.0100 | 39.5371 | 1,122.0200 | AID1469; AID1479 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 32.6427 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 35.4813 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
geminin | Homo sapiens (human) | Potency | 20.5962 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
Vpr | Human immunodeficiency virus 1 | Potency | 50.1187 | 1.5849 | 19.6264 | 63.0957 | AID651644 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
corticotropin-releasing hormone receptor 2 | Homo sapiens (human) | EC50 (µMol) | 7.0000 | 1.1200 | 11.5617 | 36.8000 | AID602473 |
corticotropin releasing factor-binding protein | Homo sapiens (human) | EC50 (µMol) | 7.0000 | 1.1200 | 11.5617 | 36.8000 | AID602473 |
insulin-degrading enzyme isoform 1 | Homo sapiens (human) | EC50 (µMol) | 54.6910 | 2.0260 | 5.1785 | 8.9430 | AID588439; AID588681 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |